Alvotech Reports an Initiation of AVT05, a Proposed Biosimilar for Simponi and Simponi Aria to Treat Moderate to Severe Rheumatoid Arthritis
Shots:
- The company initiates the P-II confirmatory patient study of AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab) evaluating the efficacy, safety, and immunogenicity of AVT05 (SC) vs EU-approved Simponi in adult patients with mod. to sev. rheumatoid arthritis
- The primary outcome measures will be to show the comparative efficacy of AVT05 vs Simponi @16wks. based on change from baseline on a standardized DAS28-CRP which evaluates the severity of RA using clinical and laboratory data
- Additionally, the company initiates PK study for AVT05 in Jan 2023. Golimumab is a mAb that inhibits tumor necrosis factor-alpha (TNF alpha)
Ref: GlobeNewswire | Image: Alvotech
Related News:- Alvotech Reports Initiation of Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
